Heart failure & cardiomyopathiesSecondary analysis
Influence of Disease-Modifying Therapy on the Efficacy of Vutrisiran in Transthyretin Cardiac Amyloidosis
- Secondary analysis of the HELIOS-B randomised trial
Authors' conclusion
In HELIOS-B, there was no statistically significant evidence that the treatment benefit of vutrisiran on all-cause mortality and recurrent cardiovascular events was modified by concomitant use of tafamidis or heart failure therapies.
Study context
- Population
- Patients with transthyretin amyloid cardiomyopathy (ATTR-CM)randomized
- Participants
- 654 patients
- Comparison
- Vutrisiran vs placebo, by concomitant disease-modifying or HF therapy
- Primary endpoint
- Composite of:
- All-cause mortality and recurrent CV events
- Treatment effect modification by concomitant therapy
Primary result
As reported in the abstract
Treatment effect modification by baseline or time-updated medication use
- Tafamidis, interaction P
- 0.95
- SGLT2 inhibitors, interaction P
- 0.59
- Mineralocorticoid receptor antagonists (MRA), interaction P
- 0.92
- Beta-blockers, interaction P
- 0.75
- ACEi/ARB/ARNI, interaction P
- 0.82
Further findings
Baseline concomitant therapy
- Receiving tafamidis
- 40%
- At least 1 HF medication
- 77%
Medication initiation during follow-up
- MRAs and SGLT2 inhibitors most frequently initiated; initiation rates numerically higher across all HF medication classes with placebo
Original publication
Influence of Disease-Modifying Therapy on the Efficacy of Vutrisiran in Transthyretin Cardiac Amyloidosis. J Am Coll Cardiol. Published 30 August 2026. doi:10.1016/j.jacc.2026.07.023
Summarised from the published abstract; every number is checked against it